The spectrum of genetic mutations in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 6, 2015, Pages 2177-2185

  Sheikh, Asfandyar ^a   Hussain, Syed Ather ^a   Ghori, Quratulain ^b   Naeem, Nida ^c   Fazil, Abul ^d   Giri, Smith ^e   Sathian, Brijesh ^f   Mainali, Prajeena ^g   Al Tamimi, Dalal M ^h  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b JINNAH SINDH MEDICAL UNIVERSITY   (Pakistan)

^c CIVIL HOSPITAL   (Pakistan)

^d KASTURBA MEDICAL COLLEGE   (India)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

^g EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^h IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

BRCA1; BRCA2; Breast cancer; Genetic mutations

Indexed keywords

TUMOR MARKER;

BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 84929207626     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.6.2177     Document Type: Short Survey

References (125)

1. Ahmed M, Rahman N (2006). ATM and breast cancer susceptibility. Oncogene, 25, 5906-11.
2. Akhtari-Zavare M, Ghanbari-Baghestan A, Latiff LA, Matinnia N, Hoseini N (2014). Knowledge of breast cancer and breast self-examination practice among Iranian women in Hamedan, Iran. Asian Pac J Cancer Prev, 15, 6531-4.
3. Al-Tamimi DM, Bernard PS, Shawarby MA, Al-Amri AM, Hadi MA (2009). Distribution of molecular breast cancer subtypes in Middle Eastern-Saudi Arabian women: a pilot study. Ultrastruct Pathol, 33, 141-50.
4. Al-Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer: a Saudi population based study. BMC Cancer, 10, 223.
5. Antoniou A, Pharoah PD, Narod S, et al (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72, 1117-30.
6. Badar F, Faruqui ZS, Uddin N, et al (2011). Management of breast lesions by breast physicians in a heavily populated south asian developing country. Asian Pac J Cancer Prev, 12, 827-32.
7. Benusiglio PR, Malka D, Rouleau E, et al (2013). CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet, 50, 486-9.
8. Bertwistle D, Ashworth A (1998). Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev, 8, 14-20.
9. Berx G, Cleton-Jansen AM, Nollet F, et al (1995). Ecadherinis a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J, 14, 6107-15.
10. Berx G, van Roy F (2001). The E-cadherin/catenin complex: an important gate keeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res, 3, 289-93.
11. Bogdanova N, Feshchenko S, Schurmann P, et al (2008). Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer, 122, 802-6.
12. Bojesen SE, Pooley KA, Johnatty SE, et al (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet, 45, 371-84.
13. Bork P, Blomberg N, Nilges M (1996). Internal repeats in the BRCA2 protein sequence. Nat Genet, 13, 22-3.
14. Bouguerra H, Guissouma H, Labidi S, et al (2014). Breast cancer in Tunisia: association of body mass index with histopathological aspects of tumors. Asian Pac J Cancer Prev, 15, 6805-10.
15. Buisson R, Dion-Cote AM, Coulombe Y, et al (2010). Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol, 17, 1247-54.
16. Cantor SB, Bell DW, Ganesan S, et al (2001). BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell, 105, 149-60.
17. Carney JP, Maser RS, Olivares H, et al (1998). The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell, 93, 477-86.
18. Casadei S, Norquist BM, Walsh T, et al (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res, 71, 2222-9.
19. Chapman MS, Verma IM (1996). Transcriptional activation by BRCA1. Nature, 382, 678-9.
20. Chaturvedi P, Eng WK, Zhu Y, et al (1999). Mammalian Chk2 is a downstream effector of the ATM-dependent DNAdamage checkpoint pathway. Oncogene, 18, 4047-54.
21. Chauhan A, Subba SH, Menezes RG, et al (2011). Younger women are affected by breast cancer in South India: a hospital based descriptive study. Asian Pac J Cancer Prev, 12, 709-11.
22. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev, 14, 278-88.
23. CHEK2 Breast Cancer Case-Control Consortium (2004). CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet, 74, 1175-82.
24. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan Z-Q (2002). Autoubiquitination of the BRCA1· BARD1 RING ubiquitin ligase. J Biol Chem, 277, 22085-92.
25. Chen PL, Chen CF, Chen Y, et al (1998). The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A, 95, 5287-92.
26. Chong L, Sankavaram K, Freake HC (2011). LIV-1 regulates zinc uptake and E-cadherin (CDH1) expression in MDA-MB-231 breast cancer cells but does not influence SNAI1. FASEB J, 25, 979-2.
27. Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D (2012). Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J, 1, 1.
28. Cleton-Jansen AM, Callen DF, Seshadri R, et al (2001). Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res, 61, 1171-77.
29. Cleton-Jansen AM (2002). E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res, 4, 5-8.
30. Collins N, McManus R, Wooster R, et al (1995). Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene, 10, 1673-75.
31. Conway AB, Lynch TW, Zhang Y, et al (2004). Crystal structure of a Rad51 filament. Nat Struct Mol Biol, 11, 791-6.
32. Coussens L, Yang-Feng TL, Liao YC, et al (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-9.
33. Davies OR, Pellegrini L (2007). Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat Struct Mol Biol, 14, 475-83.
34. De Abreu FB, Pirolo LJ, CanevariRde A, et al (2007). Shorter CAG repeat in the AR gene is associated with atypical hyperplasia andbreast carcinoma. Anticancer Res, 27, 1199-205.
35. De Nicolo A, Tancredi M, Lombardi G, et al (2008). A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res, 14, 4672-80.
36. Dick MG, Masciari S, Miron A, et al (2011). P1-09-03: Prevalence of germline TP53 mutations in young women with HER2-positive breast cancer. Cancer Res, 71.
37. Donenberg T, Lunn J, Curling D, et al (2011). A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast cancer Res Treat, 125, 591-6.
38. Durgan J, Kaji N, Jin D, Hall A (2011). Par6B and atypical PKC regulate mitotic spindle orientation during epithelial morphogenesis. J Biol Chem, 286, 12461-74.
39. Emens LA (2005). Trastuzumab: targeted therapy for the management of HER-2/neu overexpressing metastatic breast cancer. Am J Ther, 12, 243-53.
40. Erbil N, Bolukbas N (2014). Health beliefs and breast self-examination among female university nursing students in Turkey. Asian Pac J Cancer Prev, 15, 6525-9.
41. Esteller M, Fraga MF, Guo M, et al (2001). DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet, 10, 3001-7.
42. Fallahzadeh H, Momayyezi M, Akhundzardeini R, Zarezardeini S (2014). Five year survival of women with breast cancer in Yazd. Asian Pac J Cancer Prev, 15, 6597-601.
43. Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene, 24, 3726-36.
44. Fostira F, Tsitlaidou M, Papadimitriou C, et al (2012). Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat, 134, 353-62.
45. Fostira F, Konstantopoulou I, Mavroudis D, et al (2014). Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. Clin Genet. (in Press).
46. Goldgar DE, Healey S, Dowty JG, et al (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res, 13, 73.
47. Gomes MC, Kotsopoulos J, de Almeida GL, et al (2012). The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract, 10, 3.
48. Gonzalez-Angulo AM, Timms KM, Liu S, et al (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res, 17, 1082-9.
49. Hall JM, Lee MK, Newman B, (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684-9.
50. Hao Y, Montiel R, Li B, et al (2010). Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 815-20.
51. Heitzer E, Lax S, Lafer I, et al (2013). Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma. BMC Med Genet, 14, 129.
52. Hennig G, Lowrick O, Birchmeier W, Behrens J (1996). Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem, 271, 595-602.
53. Hisatomi H, Nagao K, Wakita K, Kohno N (2002). ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis. Oncol, 62, 136-40.
54. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H (2009). LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev, 89, 777-98.
55. Joosse SA (2012). BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes. Nat Rev Cancer, 12, 372.
56. Jemal A, Bray F, Center MM, et al (2011). Global Cancer statistics. Ca Cancer J Clin, 61, 69-90.
57. Kanaga KC, Nithiya J, Shatirah MF (2011). Awareness of breast cancer and screening procedures among Malaysian women. Asian Pac J Cancer Prev, 12, 1965-7.
58. Karadag G, Gungormus Z, Surucu R, Savas E, Bicer F (2014). Awareness and practices regarding breast and cervical cancer among Turkish women in Gazientep. Asian Pac J Cancer Prev, 15, 1093-8.
59. Kern SE, Kinzler KW, Bruskin A, et al (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science, 252, 1708-11.
60. Kinoshita E, van der Linden E, Sanchez H, Wyman C (2009). RAD50, an SMC family member with multiple roles in DNA break repair: how does ATP affect function? Chromosome Res, 17, 277-88.
61. Kobayashi J (2004). Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to gamma-H2AX through FHA/BRCT domain. J Radiat Res, 45, 473-8.
62. Launonen V (2005). Mutations in the human LKB1/STK11 gene. Hum Mutat, 26, 291-7.
63. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH (2000). hCds1-mediated phosphorylation of BRCA1regulates the DNA damage response. Nature, 404, 201-4.
64. Lewis AG, Flanagan J, Marsh A, et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res, 7, 1005-16.
65. Loman N, Johannsson O, Bendahl PO, et al (1998). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 83, 310-9.
66. Lubahn DB, Joseph DR, Sullivan PM, et al (1988). Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science, 240, 327-30.
67. Luo RZ, Fang X, Marquez R, et al (2003). ARHI is a Ras related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene, 22, 2897-909.
68. Luo RZ, Peng H, Xu F, et al (2001). Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta, 1519, 216-22.
69. Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6, 457-70.
70. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
71. Manie E, Vincent-Salomon A, Lehmann-Che J, et al (2009). High frequency of TP53 mutation in BRCA1 and sporadic basallike carcinomas but not in BRCA1 luminal breast tumors. Cancer Res, 69, 663-71.
72. Masciari S, Dillon DA, Rath M, et al (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-fraumeni syndrome consortium effort. Breast Cancer Res Treat, 133, 1125-30.
73. Menichini P, Linial M (2001). SUVi and BACH1: a new subfamily of mammalian helicases? Mutat Res, 487, 67-71.
74. Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
75. Mizuta R, LaSalle JM, Cheng HL, et al (1997). RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci USA, 94, 6927-32.
76. Natt E, Magenis RE, Zimmer J, Mansouri A, Scherer G (1989). Regional assignment of the human loci for uvomorulin (UVO) and chymotrypsinogen B (CTRB) with the help of two overlapping deletions on the long arm of chromosome 16. Cytogenet Cell Genet, 50, 145-8.
77. Norsa'adah B, Rahmah MA, Rampal KG, Knight A (2012). Understanding barriers to Malaysian women with breast cancer seeking help. Asian Pac J Cancer Prev, 13, 3723-30.
78. Norlaili AA, Fatihah MA, Daliana NF, Maznah D (2013). Breast cancer awareness of rural women in Malaysia: is it the same as in the cities? Asian Pac J Cancer Prev, 14, 7161-4.
79. Olayioye MA (2001). Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res, 3, 385-9.
80. Pabalan N, Jarjanazi H, Ozcelik H (2013). Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 137, 553-8.
81. Prokopcova J, Kleibl Z, Banwell CM, Pohlreich P (2007). The role of ATM in breast cancer development. Breast Cancer Res Treat, 104, 121-8.
82. Radi SM (2013). Breast cancer awareness among Saudi females in Jeddah. Asian Pac J Cancer Prev, 14, 4307-12.
83. Ravichandran K, Mohamed G, Al-Hamdan NA (2010). Public knowledge on cancer and its determinants among Saudis in the Riyadh Region of Saudi Arabia. Asian Pac J Cancer Prev, 11, 1175-80.
84. Rahman N, Seal S, Thompson D, et al (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet, 39, 165-7.
85. Rebbeck TR, Kantoff PW, Krithivas K, et al (1999). Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet, 64, 1371-7.
86. Renwick A, Thompson D, Seal S, et al (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet, 38, 873-5.
87. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009). Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet, 17, 722-31.
88. Rodriguez MC, Songyang Z (2008). BRCT domains: phosphopeptide binding and signaling modules. Front Biosci, 13, 5905-15.
89. Rosmawati NH (2010). The usage and knowledge of mammography among women in sub-urban area in Terengganu, Malaysia. Asian Pac J Cancer Prev, 11, 767-71.
90. Sanchez-Cespedes M, Parrella P, Esteller M, et al (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res, 62, 3659-62.
91. Sathian B, Nagaraja SB, Banerjee I, et al (2014). Awareness of Breast Cancer Warning Signs and Screening Methods among female residents of Pokhara Valley, Nepal. Asian Pac J Cancer Prev, 15, 4723-6.
92. Savitsky K, Bar-Shira A, Gilad S, et al (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 268, 1749-53.
93. Schrader KA, Masciari S, Boyd N, et al (2011). Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet, 48, 64-8.
94. Seal S, Thompson D, Renwick A, et al (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet, 38, 1239-41.
95. Serey VH, Kim ES, Monchy D (2011). Preliminary data about female malignant breast tumours in Cambodia. Asian Pac J Cancer Prev, 12, 383-5.
96. Shallwani K, Ramji R, Ali TS, Khuwaja AK (2010). Self examination for breast and testicularcancers: a community-based intervention study. Asian Pac J Cancer Prev, 11, 383-6.
97. Shawarby MA, Al-Tamimi DM, Ahmed A (2011). Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. Diagn pathol, 6, 57.
98. Shiloh Y (2006). The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci, 31, 402-10.
99. Shuen AY, Foulkes WD (2011). Inherited mutations in breast cancer genes-Risk and response. J Mammary Gland Biol Neoplasia, 16, 3-15.
100. Silwal-Pandit L, Vollan HKM, Chin SF, et al (2014). TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res, 20, 3569-80.
101. Smith TR, Liu-Mares W, Van Emburgh BO, et al (2011). Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. Carcinogenesis, 32, 1354-60.
102. Song H, Ramus SJ, Kjaer SK, et al (2007). Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One, 2, 268.
103. Sreedevi A, Quereshi MA, Kurian B, Kamalamma L (2014). Screening for breast cancer in a low middle income country: predictors in a rural area of Kerala, India. Asian Pac J Cancer Prev, 15, 1919-24.
104. Sreedharan J, Muttappallymyalil J, Venkatramana M, Thomas M (2010). Breast self-examination: knowledge and practice among nurses in United Arab Emirates. Asian Pac J Cancer Prev, 11, 651-4.
105. Steffen J, Nowakowska D, Niwinska A, et al (2006). Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer, 119, 472-5.
106. Tan M, Yu D (2007). Molecular mechanisms of erbB2-mediated breast cancer chemo resistance. Adv Exp Med Biol, 608, 119-29.
107. Thai TH, Du F, Tsan JT, et al (1998). Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarianand uterine cancers. Hum Mol Genet, 7, 195-202.
108. van der Groep P, van der Wall E, van Diest PJ (2011). Pathology of hereditary breast cancer. Cell Oncol (Dordr), 34, 71-88.
109. van Lier MG, Westerman AM, Wagner A, et al (2011). High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut, 60, 141-7.
110. Varley J (2003). TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol, 222, 117-129.
111. Varley JM (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat, 21, 313-20.
112. Walsh T, Lee MK, Casadei S, et al (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA, 107, 12629-33.
113. Warner E, Hill K, Causer P, et al (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol, 29, 1664-9.
114. Westermark UK, Reyngold M, Olshen AB, et al (2003). BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol, 23, 7926-36.
115. Williams T, Brenman JE (2008). LKB1 and AMPK in cell polarity and division. Trends Cell Biol, 18, 193-8.
116. Wooster R, Bignell G, Lancaster J, et al (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-92.
117. Wooster R, Neuhausen SL, Mangion J, et al (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 265, 2088-90.
118. Wu MH, Chou YC, Yu CP, et al (2008). Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility. Eur J Cancer Prev, 17, 317-22.
119. Wu TY, Chung S, Yeh MC, et al (2012). Understanding breast cancer screening practices in Taiwan: a country with universal health care. Asian Pac J Cancer Prev, 13, 4289-94.
120. Xia B, Sheng Q, Nakanishi K, et al (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, 22, 719-29.
121. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP (2000). Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat, 59, 153-61.
122. Yu Y, Luo R, Lu Z, et al (2006). Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene, whose expression is lost in ovarian and breast cancers. Methods Enzymol, 407, 455-68.
123. Zhang B, Beeghly-Fadiel A, Long J, Zheng W (2011). Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol, 12, 477-88.
124. Zhang F, Ma J, Wu J, et al (2009). PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol, 19, 524-9.
125. Zhu Y, Xie Y, Liu F, et al (2014). Systemic analysis on risk factors for breast cancer related lymphedema. Asian Pac J Cancer Prev, 15, 6535-41.